Ameriprise Financial heads into the final stretch before its October 28 earnings with short sellers quietly rebuilding positions into a softening price trend — while the lending market itself remains extraordinarily relaxed.
The most notable development this week is the pace of short accumulation. Short interest has climbed 14% over the past week to 3.1% of the free float — a meaningful move in percentage terms, even if the absolute level remains modest. The rebuild began sharply around September 9, when shares jumped from roughly 2.5 million to 2.83 million short in a single session, and has since continued grinding higher. The stock has responded in kind: down 2.4% on the week to $544.33, extending a 3.2% one-month slide. Yet the borrow market tells a different story. Availability is extraordinarily loose at more than 4,600% — meaning there are roughly 46 times as many shares available to lend as are currently borrowed. Cost to borrow is just under 0.50%, near multi-month lows. None of this suggests a squeezed or crowded short position. The ORTEX short score has also drifted modestly higher, from around 36.5 at the start of last week to 38.6 by September 17 — a creeping rather than dramatic shift in short-side pressure.
Options positioning is calm by most measures. The put/call ratio is 0.43, marginally above its 20-day average of 0.40 and less than one standard deviation away from that mean. The ratio did jump noticeably from its August range of 0.36–0.37 into the 0.43 zone starting September 9 — roughly coinciding with the short interest pop — but the z-score of 0.89 means this is background noise rather than a strong defensive signal. The 52-week high on the PCR is 1.65, a level not remotely approached. Overall, positioning looks cautious rather than alarmed.
On the Street, analysts have been broadly constructive but measured. Recent coverage — running from early July — saw targets raised across the board after Q2 results beat expectations. Morgan Stanley's Michael Cyprys, maintaining an Underweight, lifted his target to $489. Keefe Bruyette moved to $545, and Jefferies holds a Buy with a $645 target. Evercore sits at $625. The mean target across the group is approximately $579, implying roughly 6% upside from current levels. That modest gap reflects a market fairly well covered by analyst expectations. Valuation corroborates the measured tone: the P/E has drifted lower over 30 days, now near 10.9x, while EV/EBITDA has edged up slightly to 6.3x. The EV/EBIT factor ranks in the 86th percentile of the ORTEX universe — Ameriprise screens as genuinely cheap relative to its earnings power. EPS surprise ranks in the 77th percentile, and 90-day EPS momentum is at the 78th — the company has a consistent record of beating estimates.
The bear case centres on pressure within the asset management segment: deposit deceleration, rising withdrawals, and legacy insurance outflows have weighed on flows. Bulls point to nearly $1.2 trillion in wealth management assets, a 10,600-strong advisor force, and a capital return framework that routes around 80% of operating earnings back to shareholders — a profile that scores in the 99th percentile on the ORTEX dividend factor, though dividend history data in the available dataset only runs to mid-2022 and cannot be relied upon for current yield calculations.
Insider activity through the most recent filings (to August 10) leaned negative in net terms. The SVP and Controller sold 472 shares at roughly $559, and the EVP of Marketing sold 2,400 shares outright at $558 for approximately $1.3 million in proceeds — both open-market transactions, neither under a 10b5-1 plan. Option exercises and tax-withholding events accompanied those sales but are compensation mechanics rather than conviction signals. Net insider selling over the 90-day window totals around 54,000 shares at a net value of approximately $29 million. That is a meaningful negative flow, though it is worth noting none of the named sellers are the CEO or CFO. On the institutional side, the register is predictably stable: BlackRock holds 9.0% and Vanguard entities collectively own over 13%, with State Street adding 80,000 shares in the most recent period. No activist 13D has been filed; all 13D/G holders are passive index and institutional holders.
Closest peer RJF fell 5.0% on the week, and LPLA dropped 7.3% — AMP's 2.4% decline looks relatively contained against that group. The widest divergence came from BLK, off less than 1%, suggesting sector rotation within financials rather than any company-specific story.
The October 28 print is the next hard catalyst. Q2 delivered a small positive price move on the day and a 3.3% gain over the following five sessions; the April print produced a 1.6% decline. Neither outcome was dramatic. With the short score at a modest 38.6, borrow availability loose, and the PCR barely above its recent average, the setup into Q3 results is less about short-side pressure and more about whether flow dynamics in the asset management segment show signs of stabilising.
See the live data behind this article on ORTEX.
Open AMP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
